Format

Send to

Choose Destination
See comment in PubMed Commons below
Exp Neurol. 2012 Dec;238(2):133-7. doi: 10.1016/j.expneurol.2012.08.012. Epub 2012 Aug 19.

In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease.

Author information

1
Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Germany.

Abstract

The oral antidiabetic thiazolidinediones exert protective effects in models of Parkinson's disease and other neurological diseases. While the antidiabetic effect is due to activation of PPARγ, the mechanisms underlying the neuroprotection are more controversial. It may involve activation of PPARγ blocking inflammation and apoptosis. However, new evidence suggests an antioxidative PPARγ-independent action. Here we discuss recent data on the mode of action of TZDs in models of PD and their implication for the translation into the clinic.

PMID:
23085103
DOI:
10.1016/j.expneurol.2012.08.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center